Philip Morris International
PM
$208.79
+0.14%
Philip Morris International is a global tobacco and nicotine company that sells combustible cigarettes alongside a growing portfolio of reduced-risk products, including IQOS heated tobacco, Zyn nicotine pouches, and Veev vapes, operating primarily outside the United States with an expanding US presence following the 2023 Swedish Match acquisition. PMI is the clear category leader in heated tobacco and nicotine pouches across most international markets, giving it a distinct dual identity as both a legacy cash-generative cigarette franchise and the most credible smoke-free transition platform among global tobacco majors. The current investor narrative centers on the durability of that smoke-free pivot: the most recent Q3 2026 results beat estimates on strong pricing and sales growth, management raised full-year guidance and lifted the dividend, reinforcing the thesis that reduced-risk products can offset combustible volume declines. Debate now hinges on whether Zyn and IQOS momentum can sustain premium multiples amid FDA nicotine-pouch regulation and intensifying competition from smaller players like Turning Point Brands.…
PM
Philip Morris International
$208.79
Related headlines
PM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $210.47 and implied upside of +0.8% versus the current price.
Average Target
$210.47
0 analysts
Implied Upside
+0.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $230
Analyst target range
Coverage is solid with 15 analysts, and sentiment is firmly bullish: the consensus recommendation is "buy" with a mean rating of 1.69 on a 1-to-5 scale where lower is more bullish. The average target price of $210.47 implies about 5.5% upside from the current $199.47, a modest but positive expected return that is typical for a large-cap defensive name already near its highs. Recent institutional actions support the constructive stance, with Citigroup, Barclays, Morgan Stanley, Needham, and Stifel all maintaining Buy or Overweight ratings through the summer and fall of 2026, while UBS remains the notable Neutral holdout.
The target range spans $175 to $230, a spread of roughly 31% around the average, which signals moderate conviction rather than a tight consensus. The high target of $230 assumes continued smoke-free share gains, Zyn and IQOS volume acceleration, and further multiple expansion on raised guidance, while the low target of $175 prices in margin compression from regulatory pressure on nicotine pouches or a slowdown in pricing power. The consensus EPS estimate of $12.06 (range $11.74-$12.43) and revenue estimate of $53.23 billion (range $52.13-$54.50 billion) are tightly clustered, indicating high confidence in near-term fundamentals even if the price targets diverge on multiple assumptions.
Drowning in data?
Find the real signal!
Bulls vs Bears: PM Investment Factors
The bull case currently holds stronger evidence: 10.37% revenue growth, 40.48% operating margins expanding 348bps YoY, 93% FCF conversion, a raised dividend, and a buy consensus with a $210.47 target all point the same direction. The bear case rests less on fundamentals than on price — 22.06x PE and 8.30x EV/Sales already embed a successful smoke-free transition, and the 5.5% upside to consensus is thin for a stock 84% up its 52-week range. The single most important tension is whether Zyn and IQOS volume momentum can outrun FDA pouch regulation and competition from smaller players like Turning Point Brands; if it can, the premium multiple is deserved and the stock breaks $210.45, but if regulation bites, the multiple compresses toward the mid-teens and the $175 low target becomes live.
Bullish
- Smoke-free mix now 41.5% of revenue: Reduced-risk products contributed $4.645 billion of the $11.192 billion disclosed product revenue in Q2 2026, versus $6.547 billion from combustibles. This is the highest-quality growth engine in global tobacco, and it is the structural reason PM can grow revenue 10.37% YoY while legacy peers stagnate.
- Revenue growth accelerating to 10.37%: Q2 2026 revenue of $11.192 billion rose 10.37% from $10.14 billion a year earlier, and the sequential path ($10.362B Q4 2025 → $10.146B Q1 2026 → $11.192B Q2 2026) confirms a rising trajectory. Q3 2026 results subsequently beat estimates on strong pricing and sales growth, with management raising full-year guidance.
- Operating margin expanded 348bps YoY: Q2 2026 operating margin reached 40.48% versus 37.01% in Q2 2025 and 32.55% in Q4 2025, while gross margin rose to 68.43% from 67.66%. Pricing power plus operating leverage is converting top-line growth into disproportionate profit growth.
- FCF conversion of 93% funds the dividend: Q2 2026 generated $5.112 billion of free cash flow on $5.492 billion of operating cash flow against only $380 million of capex, with trailing FCF of $12.722 billion. The 3.46% dividend yield is covered at a 75.99% payout ratio, and management just lifted the dividend again.
Bearish
- Valuation at premium to tobacco history: At 22.06x trailing and 21.94x forward PE, plus 15.68x EV/EBITDA and 8.30x EV/Sales, PM trades well above the industry's historical mid-teens multiples. The market is already paying for the smoke-free transition, leaving little room for disappointment.
- Tiny 5.5% upside to consensus target: The $210.47 average target sits only 5.5% above the $199.47 price and just below the 52-week high of $210.45, meaning the stock is already near where the Street thinks it belongs. The $175 low target implies 12.3% downside, a worse skew than the upside.
- Negative book value and tight liquidity: Debt-to-equity of -4.89 and a negative book value (PB of -24.97) reflect an aggressive capital structure from buybacks and the Swedish Match deal. The current ratio of 0.958 and quick ratio of 0.549 leave thin liquidity cushion, and the Q1 2026 FCF deficit of -$752 million shows seasonal cash strain.
- Regulatory risk on nicotine pouches: FDA nicotine-pouch regulation is the central threat to the Zyn growth story, and the August 2026 Turning Point Brands coverage highlights how rule changes could reshape category share. Any adverse ruling would hit the highest-multiple part of PM's portfolio.
PM Technical Analysis
PM is in a sustained, well-established uptrend, with the stock up 26.49% over the past year and 24.44% year-to-date, materially outperforming the S&P 500's 13.13% and 11.45% respective gains. At the current price of $199.47, the stock sits at roughly 84% of its 52-week range of $142.11 to $210.45, positioning it in the upper portion of the band but still about 5.2% below the high. That positioning signals persistent momentum rather than overextension, since the stock has repeatedly consolidated rather than spiking into the high, and the 19.26% max drawdown over the period shows pullbacks have been contained and bought.
Short-term momentum is constructive but decelerating relative to the longer trend. The stock is up 4.52% over the past month and 3.35% over three months, meaning the 1-month gain exceeds the 3-month gain, a pattern of re-acceleration after a mid-summer consolidation near $185-$190. Relative strength confirms leadership: PM beat SPY by 5.54 percentage points over one month and 15.03 points over six months, though the 3-month relative strength of just 0.50 points shows the stock moved roughly in line with the market during the summer lull. The most recent session saw a modest 1.13% pullback from $201.74 to $199.47 on volume of about 3.58 million shares, a normal digestion day rather than distribution.
Key technical levels are well defined. Resistance sits at the 52-week high of $210.45, and a decisive breakout above that level would confirm the uptrend's continuation and likely invite momentum and dividend-growth funds to add exposure. Support is anchored by the 52-week low of $142.11, with intermediate support in the $185-$190 zone where the stock consolidated in August and September. The short ratio of 4.04 days indicates short interest is moderate and not a major squeeze catalyst, while the 19.26% max drawdown underscores that this is a lower-volatility defensive name where position sizing can be more generous than for high-beta growth stocks.
Beta
0.36
0.36x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$142-$214
Price range past year
Annual Return
+43.2%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +9.4% | -0.9% |
| 3m | +9.4% | +1.2% |
| 6m | +25.5% | +4.9% |
| 1y | +43.2% | +11.2% |
| ytd | +30.2% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
Revenue is growing at a healthy clip and accelerating. Q2 2026 revenue came in at $11.192 billion, up 10.37% year-over-year versus $10.14 billion in Q2 2025, and the sequential progression from $10.146 billion in Q1 2026 and $10.362 billion in Q4 2025 confirms a rising trajectory. Segment data shows the mix shift clearly: combustible products generated $6.547 billion while reduced-risk products contributed $4.645 billion, meaning smoke-free now represents roughly 41.5% of the disclosed product revenue base. That mix is the key driver of both growth and multiple expansion, since reduced-risk categories carry structurally higher growth and pricing power than cigarettes.
Profitability is robust and margins are expanding. Q2 2026 net income reached $2.817 billion on a 25.17% net margin, with gross margin of 68.43% versus 67.66% in Q2 2025 and 65.64% in Q4 2025, a clear upward trend. Operating margin of 40.48% in Q2 2026 compares favorably to 37.01% a year earlier and 32.55% in Q4 2025, reflecting pricing power and operating leverage. The trailing net margin of 27.92% and operating margin of 36.64% are strong for the consumer defensive space, and the 67.12% gross margin profile is consistent with a premium tobacco franchise.
Balance sheet and cash flow present a mixed but manageable picture. Trailing free cash flow is $12.722 billion, and Q2 2026 alone generated $5.112 billion of FCF on $5.492 billion of operating cash flow against just $380 million of capex, a 93% FCF conversion rate. However, the current ratio of 0.958 and quick ratio of 0.549 indicate tight liquidity, and the negative debt-to-equity of -4.89 and negative book value reflect an aggressive capital structure shaped by buybacks and the Swedish Match deal; interest coverage of 18.6x and a 75.99% payout ratio show the dividend is covered but leaves limited cushion. The Q1 2026 FCF deficit of -$752 million was seasonal working capital, not structural, given the strong Q2 rebound.
Quarterly Revenue
$11.2B
2026-06
Revenue YoY Growth
+10.4%
YoY Comparison
Gross Margin
68.4%
Latest Quarter
Free Cash Flow
$12.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Because PM is profitable with trailing net income of roughly $11.3 billion annualized, the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 22.06x and a forward PE of 21.94x, an unusually narrow gap that implies the market expects only modest earnings growth near-term, consistent with the consensus EPS estimate of $12.06. The PEG ratio of 0.365 is strikingly low, suggesting the valuation is cheap relative to expected growth, though this is partly an artifact of the low forward EPS base relative to the $199.47 price.
Against the broader market and defensive peers, PM's 22.06x trailing PE and 6.14x PS ratio represent a premium to the tobacco industry's historical mid-teens multiples, but the premium is justified by superior growth: 10.37% revenue growth and expanding 40%+ operating margins are well above the flat-to-declining profile of legacy cigarette peers. The EV/EBITDA of 15.68x and EV/Sales of 8.30x are elevated for consumer staples, reflecting the market's willingness to pay for the smoke-free transition, while the 3.46% dividend yield remains competitive versus bonds and supports the total-return case.
Historically, PM's PE has ranged from roughly 15x to 29x over the past several years, with the current 22.06x sitting near the middle of that band and well below the 25.1x-29.3x levels seen in mid-2026 and late 2025. The PS ratio of 6.14x is near the low end of its historical range of roughly 16x-28x on the older data series, though methodology differences make that comparison imperfect. Net-net, the stock is not priced at euphoric highs on earnings, leaving room for multiple support if guidance continues to be raised.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the capital structure and the dividend commitment. Debt-to-equity of -4.89 and a negative book value (PB -24.97) reflect heavy borrowing layered with buybacks and the Swedish Match deal, while the current ratio of 0.958 and quick ratio of 0.549 leave little short-term cushion. The 75.99% payout ratio on a 3.46% yield means the dividend consumes most of earnings, so a pricing or volume shock would force a choice between the payout and deleveraging. The Q1 2026 free cash flow deficit of -$752 million, even if seasonal, shows how quickly working capital can swing cash generation against a $12.722 billion TTM FCF base.
Market and competitive risks are dominated by valuation compression and regulation. At 22.06x trailing PE, 15.68x EV/EBITDA and 8.30x EV/Sales, PM trades at a clear premium to the tobacco industry's mid-teens historical multiples, so any deceleration in the 10.37% revenue growth would compress the multiple toward that band. FDA nicotine-pouch regulation is the most concrete external threat, with the August 2026 Turning Point Brands coverage illustrating how rule changes could redistribute category share, and smaller competitors are targeting the same pouch growth. The stock's defensive profile has been rewarded — up 26.49% over a year versus SPY's 13.13% — but that outperformance makes it vulnerable to sector rotation if investors rotate back toward cyclical or higher-beta exposure.
In a worst case, adverse FDA pouch rules combine with a combustible volume acceleration and a guidance cut, forcing the market to re-rate PM from 22x toward the mid-teens on earnings. That would put the shares near the analyst low target of $175, roughly 12.3% below the current $199.47, and a deeper de-rating toward the 52-week low of $142.11 would mean a 28.8% loss. The 19.26% max drawdown over the past year is a realistic guide to how far a sentiment shock can carry the stock even without a fundamental break. An investor should size positions assuming a 13-29% drawdown is plausible in an adverse regulatory scenario.